Market Research Logo

Global Biosimilars Partnering Terms and Agreements 2014 to 2019

Global Biosimilars Partnering Terms and Agreements 2014 to 2019

The Global Biosimilars Partnering Terms and Agreements 2014 to 2019 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in Biosimilars partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Biosimilars partnering contract documents
Top Biosimilars deals by value

The Global Biosimilars Partnering Terms and Agreements report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Biosimilars dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biosimilars dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Biosimilars deals since 2014. Deals are listed by headline value, signed by big pharma, most active Biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Biosimilars dealmaking with a brief summary followed by a comprehensive listing of Biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2014. The chapter is organized by specific Biosimilars technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Biosimilars partnering company A-Z, deal type definitions and Biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Biosimilars partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biosimilars technologies and products.

Report scope

Global Biosimilars Partnering Terms and Agreements 2014 to 2019 is intended to provide the reader with an in-depth understanding and access to Biosimilars trends and structure of deals entered into by leading companies worldwide.

Global Biosimilars Partnering Terms and Agreements 2014 to 2019 includes:

Trends in Biosimilars dealmaking in the biopharma industry since 2014
Analysis of Biosimilars deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Biosimilars deals
Access to over 70 Biosimilars deal records and contract documents where available
The leading Biosimilar deals by value since 2014
Most active Biosimilars dealmakers since 2014
The leading Biosimilars partnering resources

In Global Biosimilars Partnering Terms and Agreements 2014 to 2019, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


  • Executive Summary
  • Introduction
  • Trends in Biosimilar dealmaking
    • Introduction
    • Biosimilar partnering over the years
    • Most active Biosimilar dealmakers
    • Biosimilar partnering by deal type
    • Biosimilar partnering by therapy area
    • Biosimilar partnering by technology type
    • Deal terms for Biosimilar partnering
      • Biosimilar partnering headline values
        • Table Biosimilar deals with a headline value
      • Biosimilar deal upfront payments
        • Table Biosimilar deals with an upfront value
      • Biosimilar deal milestone payments
        • Table Biosimilar deals with a milestone value
      • Biosimilar royalty rates
        • Table Biosimilar deals with a royalty rate value
  • Leading Biosimilar deals
    • Introduction
    • Top Biosimilar deals by value
      • Table Top Biosimilar deals by value since 2014
  • Most active Biosimilar dealmakers
    • Introduction
    • Most active Biosimilar dealmakers
    • Most active Biosimilar partnering company profiles
      • Selexis
      • Turgut Ilaclari
      • Mylan Pharmaceuticals
      • Xbrane Bioscience
      • Cipla
      • Epirus Biopharmaceuticals
      • Mylan Laboratories
      • Oncobiologics
      • Samsung Bioepis
      • Abbvie
      • Amgen
      • Catalent Pharma Solutions
      • Celltrion
      • Coherus Biosciences
      • EMD Millipore
      • Hospira
      • Lupin
      • Mabion
      • PharmaPraxis
      • PlantForm
      • Premier Inc
      • Prestige BioPharma
      • Sandoz
      • 3SBio
      • Abreos Biosciences
  • Biosimilar contracts dealmaking directory
    • Introduction
    • Biosimilar contracts dealmaking directory
  • Biosimilar dealmaking by technology type
    • Biosimilars/Bio-betters
  • Partnering resource center
    • Online partnering
    • Partnering events
  • Appendices
    • Biosimilar deals by company A-Z
      • 3SBio
      • Abbvie
      • Abreos Biosciences
      • Abzena
      • Accord Healthcare
      • Aceno Biotherapeutics
      • AdAlta
      • Aetos Biologics
      • AffaMed Therapeutics
      • Alteogen
      • Altiora
      • Alvogen
      • Alvotech
      • Amedica
      • Amgen
      • Amneal Pharmaceuticals
      • Back-A-Line
      • Bacterin International
      • Baxter International
      • Bio-Thera Solutions
      • Biocon
      • Biogen
      • BioSciencesCorp
      • Bio Farma
      • C-Bridge Capital
      • Catalent Pharma Solutions
      • CEA-Leti
      • Celares
      • Celltrion
      • Cipla
      • CJ Corp
      • Clinigen
      • Cobra Biologics
      • Coherus Biosciences
      • Cook Pharmica
      • CR Pharma
      • Daiichi Sankyo
      • Diabeloop
      • Dr. Reddy's Laboratories
      • Dyadic International
      • EirGenix
      • EMD Millipore
      • Epirus Biopharmaceuticals
      • Epivax
      • European Commission
      • Ewopharma
      • Fujifilm Kyowa Kirin Biologics
      • Fuji Pharma
      • Genentech
      • Hadasit Medical Research Services and Development
      • Helvetic Biopharma
      • Henlius Biotech
      • Hikma Pharmaceuticals
      • Hoffmann La Roche
      • Horizon 2020
      • Hospira
      • Ipca Laboratories
      • Jacobson Pharma
      • JHL Biotech
      • Laboratorios Liomont
      • LABORATORIOS SAVAL
      • Livzon Mabpharm
      • Lupin
      • Mab-Venture Biopharma
      • Mabion
      • MAbXience
      • Merck KGaA
      • MGC Diagnostics
      • Mithra Pharmaceuticals
      • Mitsubishi Chemical
      • Momenta Pharmaceuticals
      • Mylan Laboratories
      • Mylan Pharmaceuticals
      • NanoLock
      • NCPC GeneTech
      • NeuClone
      • Novo Nordisk
      • Oncobiologics
      • Pall Corporation
      • Pfenex
      • PharmaPraxis
      • PlantForm
      • Polpharma
      • Premier Inc
      • Premier Research
      • Prestige BioPharma
      • ProBioGen
      • Qilu Pharmaceutical
      • QuiaPEG Pharmaceuticals
      • Ranbaxy Laboratories
      • Revance Therapeutics
      • Samsung Bioepis
      • Sandoz
      • Sanofi
      • Selexis
      • Serum Institute of India
      • Simcere Pharmaceuticals
      • STADA Arzneimittel
      • TetraLogic Pharmaceuticals
      • Teva Pharmaceutical Industries
      • Theradiag
      • TR-Pharm
      • True Diagnostics
      • Turgut Ilaclari
      • UGA Biopharma
      • Univercells
      • Walloon Region Investment Fund
      • Walter and Eliza Hall Institute
      • Xbrane Bioscience
      • XL-Protein
      • YL Biologics
      • Yoshindo
      • Zhejiang Hisun Pharmaceutical
      • Zosano Pharma
    • Biosimilar deals by stage of development
      • Preclinical
      • Phase III
      • Regulatory
      • Marketed
      • Formulation
    • Biosimilar deals by deal type
      • Asset purchase
      • Bigpharma outlicensing
      • Co-development
      • Collaborative R&D
      • Contract Services
      • Co-promotion
      • Development
      • Distribution
      • Grant
      • Joint venture
      • Licensing
      • Manufacturing
      • Marketing
      • Research
      • Settlement
      • Spin out
      • Supply
      • Technology transfer
      • Termination
    • Biosimilar deals by therapy area
      • Multiple sclerosis
      • Psoriasis
      • Inflammatory bowel disease
      • Crohn's disease
      • Ulcerative colitis
      • Cystic Fibrosis (CF)
      • Chronic kidney disease (CKD)
      • Hematology
      • Anemia
      • Neutropenia
      • Transplantation
      • Immunology
      • Other autoimmune
      • Inflammation
      • Infectives
      • Viral
      • Diabetes
      • Type 1
      • Type 2
      • Musculoskeletal
      • Arthritis
      • Ankylosing spondylitis
      • Juvenile arthritis
      • Psoriatic arthritis
      • Rheumatoid arthritis
      • Back pain
      • Osteoporosis
      • Oncology
      • Brain cancer
      • Breast cancer
      • Colorectal cancer
      • Esophageal cancer
      • Gastric cancer
      • Kidney cancer
      • Leukemia
      • Chronic lymphocytic leukemia
      • Lung cancer
      • Non small cell lung cancer
      • Lymphoma
      • Non Hodgkin's lymphoma
      • Renal cell carcinoma
      • Symptoms
      • Chemotherapy
      • Ophthalmics
      • Age-related macular degeneration
      • Diabetic macular edema
      • Retinopathy
      • Uveitis
      • Orphan disease
      • Pediatrics
      • Idiopathic pulmonary fibrosis
    • Deal type definitions
  • About Wildwood Ventures
    • Current Partnering
    • Current Agreements
    • Recent report titles from Current Partnering

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report